Loading…

Tacrolimus initial steady state level in post-transplant cyclophosphamide-based GvHD prophylaxis regimens

Post-transplant cyclophosphamide (PTCy) combined with tacrolimus (TAC) as graft-versus-host disease (GvHD) prophylaxis post-hematopoietic cell transplantation (HCT) is safe and effective. Optimal serum levels of TAC in this combination remain undetermined. We hypothesized that TAC at initial steady...

Full description

Saved in:
Bibliographic Details
Published in:Bone marrow transplantation (Basingstoke) 2022-02, Vol.57 (2), p.232-242
Main Authors: Yao, Janny M., Yang, Dongyun, Clark, Mary C., Otoukesh, Salman, Cao, Thai, Ali, Haris, Arslan, Shukaib, Aldoss, Ibrahim, Artz, Andrew, Amanam, Idoroenyi, Salhotra, Amandeep, Pullarkat, Vinod, Sandhu, Karamjeet, Stein, Anthony, Marcucci, Guido, Forman, Stephen J., Nakamura, Ryotaro, Al Malki, Monzr M.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Post-transplant cyclophosphamide (PTCy) combined with tacrolimus (TAC) as graft-versus-host disease (GvHD) prophylaxis post-hematopoietic cell transplantation (HCT) is safe and effective. Optimal serum levels of TAC in this combination remain undetermined. We hypothesized that TAC at initial steady state (TISS) of
ISSN:0268-3369
1476-5365
DOI:10.1038/s41409-021-01528-y